Article Text

Download PDFPDF

Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al
Free
  1. Johannes W J Bijlsma
  2. on behalf of EULAR COVID-19 Task Force
    1. Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
    1. Correspondence to Dr Johannes W J Bijlsma, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht 3508 GA, The Netherlands; j.w.j.bijlsma{at}gmail.com

    Statistics from Altmetric.com

    It is great to learn that these Italian colleagues take an active and effective role in promoting vaccination in their patients. The more and earlier our patients, and also the entire population, are vaccinated, the better outcomes in health and quality of life. I am quite sure this example is followed by rheumatologists and other healthcare providers in many countries.

    Footnotes

    • Handling editor Josef S Smolen

    • Collaborators JWJ Bijlsma on behalf of EULAR COVID-19 Task Force.

    • Contributors Full contributor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles